Media ReleasesNext Science

View All Next Science News


Next Science - Zimmer complaint


Next Science Limited (ASX:NXS) (Next Science / Company) advises that it has agreed to open negotiations with Zimmer, Inc (Zimmer), a global leader in orthopaedics and hip and knee replacement surgery, in relation to commercialisation and distribution rights to Next Science’s XPerienceTM No Rinse Antimicrobial Solution.

The negotiations follow the filing of a complaint by Zimmer in the United States District Court, Northern District of Indiana, alleging they have global commercial exclusivity rights over XPerienceTM. Next Science denies the allegations and if negotiations fail, intends to vigorously defend the complaint if and when it is served on Next Science. Zimmer has indicated that it will not serve the complaint on Next Science pending the outcome of the negotiations.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.